For research use only. Not for therapeutic Use.
SU 5205（Cat No.:I009619） is a compound known as a VEGFR2 inhibitor. It specifically targets and inhibits the activity of vascular endothelial growth factor receptor 2 (VEGFR2), a receptor involved in angiogenesis, and the formation of new blood vessels. By blocking the activity of VEGFR2, SU 5205 hinders the signaling pathway associated with this receptor, thereby potentially suppressing the growth and development of blood vessels in conditions such as cancer. As a VEGFR2 inhibitor, SU 5205 may hold promise in anti-angiogenic therapy and related research areas.
| Catalog Number | I009619 |
| CAS Number | 3476-86-6 |
| Synonyms | SU 5205; SU-5205; SU5205.;2-Indolinone, 3-(p-fluorobenzylidene)- |
| Molecular Formula | C15H10FNO |
| Purity | ≥95% |
| Target | VEGFR |
| Solubility | Soluble in DMSO |
| Storage | 2-8°C |
| IUPAC Name | (3Z)-3-[(4-fluorophenyl)methylidene]-1H-indol-2-one |
| InChI | InChI=1S/C15H10FNO/c16-11-7-5-10(6-8-11)9-13-12-3-1-2-4-14(12)17-15(13)18/h1-9H,(H,17,18)/b13-9- |
| InChIKey | QIERHADIMMFZNE-LCYFTJDESA-N |
| SMILES | C1=CC=C2C(=C1)C(=CC3=CC=C(C=C3)F)C(=O)N2 |
| Reference | </br>1: Tian XF, Huang GM, Zang HL, Cao H. PACE4 regulates apoptosis in human pancreatic cancer Panc 1 cells via the mitochondrial signaling pathway. Mol Med Rep. 2016 Dec;14(6):5205-5210. doi: 10.3892/mmr.2016.5885. PubMed PMID: 27779720.</br>2: Tanaka S, Kaneko H, Kano H, Matsuno S, Suzuki S, Takai H, Otsuka T, Uejima T, Oikawa Y, Nagashima K, Kirigaya H, Sagara K, Yajima J, Sawada H, Aizawa T, Yamashita T. The predictive value of the borderline ankle-brachial index for long-term clinical outcomes: An observational cohort study. Atherosclerosis. 2016 Jul;250:69-76. doi: 10.1016/j.atherosclerosis.2016.05.014. PubMed PMID: 27182960. |
